A Phase 1/2 Trial of Bleximenib for Acute Leukemia
Phase 1/2
400
about 7 years
2+
27 sites in AZ, CA, IL +14
About this study
This trial is testing a treatment called bleximenib in people with acute leukemia. The goal is to find the best dose that's safe and effective, and then evaluate how well it works at that dose.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Bleximenib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
kinase inhibitor
Primary: Phase 1: Number of Participants with AEs by Severity, Phase 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability, Phase 1: Part 1: Percentage of Participants with Dose-Limiting Toxicity (DLT), Phase 2: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)
Secondary: Phase 1 and 2: Overall Response Rate (ORR), Phase 1: Duration of Response (DOR), Phase 2: Duration of Complete Response (CR)/Complete Remission With Partial Hematologic Recovery (CRh), Phase 2: Event-free survival (EFS), Phase 2: Measurable Residual Disease (MRD) Negativity Among Participants Achieving CR/CRh/CRi, Phase 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Phase 2: Overall survival (OS), Phase 2: Time To CR/CRh
Oncology